Semaglutide (Ozempic Pen)

Watch this video to learn how to properly inject Ozempic (semaglutide):

Ozempic is a prescription medication used to treat type 2 diabetes by helping to regulate blood sugar levels. It is not approved by the MHRA for weight loss or weight management purposes.

However, some studies have shown that people with type 2 diabetes who take Ozempic may experience weight loss as a side effect. This may be due to the medication's effects on appetite regulation and metabolism.

It is important to note that taking Ozempic for weight loss purposes should only be done under the guidance of a healthcare professional. They can help determine if the medication is appropriate for you based on your medical history and other factors. It is also important to follow the medication's prescribed dosing instructions and any other recommendations from your healthcare provider.

Ozempic and Wegovy are both brand names for injections of Semaglutide.

Novo Nordisk, the company that developed the medicine, manufactures it.

Ozempic was the sole version of Semaglutide available for numerous years.

Nevertheless, in 2020, Novo Nordisk introduced Rybelsus, a daily tablet form of Semaglutide.

Whether they prefer a weekly injection or a daily tablet, patients can now request their chosen treatment during a consultation with a qualified clinician at Farmeci.

Most current users of Semaglutide as a diabetes medication are used to using the injections, making Ozempic the most popular formulation.

Ozempic is the only form of Semaglutide that has been legally approved and licenced for the treatment of Type 2 diabetes.

Yet, the FDA in the United States has approved Semaglutide for chronic weight management, and the United Kingdom is quickly following suit by licencing this treatment under the brand name Wegovy.

The highest dose of Ozempic available is the 1.0 mg pen, as this is the best dose for treating Type 2 diabetes in adults.

Wegovy will be launched at a therapeutic dose of 2.4mg for weight control, making the dose of Semaglutide in Wegovy greater than in Ozempic.

The only difference between the two drugs is that Ozempic is licenced to treat type 2 diabetes mellitus, while Wegovy is licenced for weight management, despite the fact that both contain the same active ingredient.

A few drugs for weight loss and diabetes share the same licencing and name requirements.

Ozempic and Wegovy are both medications used to treat obesity and promote weight loss. Both drugs belong to the class of GLP-1 receptor agonists, which mimic the effects of a hormone called glucagon-like peptide-1 (GLP-1) to regulate blood sugar and appetite.

Here are some key similarities and differences between Ozempic and Wegovy:

Similarities:

• Both Ozempic and Wegovy are administered once a week by injection.
• Both drugs have been shown to be effective in promoting weight loss in clinical studies.
• Both drugs can lower blood sugar levels in people with type 2 diabetes.

Differences:

• Ozempic (semaglutide) was approved by the FDA in 2017 for the treatment of type 2 diabetes, while Wegovy (semaglutide) was approved in 2021 specifically for weight loss in people with obesity or overweight who have at least one weight-related condition.
• Wegovy has a higher dose of semaglutide than Ozempic, with a recommended starting dose of 0.25 mg per week that can be increased to 2.4 mg per week, while the maximum dose of Ozempic is 1 mg per week.
• In clinical trials, Wegovy has been shown to be more effective than Ozempic in promoting weight loss. In a 68-week study, people taking Wegovy lost an average of 16.4% of their body weight, compared to 10.4% for those taking Ozempic.
• Wegovy is more expensive than Ozempic, with a list price of £249-£299 per month compared to £149-£189 per month for Ozempic on Farmeci.com.

It's important to note that both drugs can have side effects, including nausea, diarrhea, and constipation. As with any medication, you should talk to your doctor about the potential benefits and risks of using either Ozempic or Wegovy for weight loss.